Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EBITDA (2022 - 2025)

Historic EBITDA for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$33.7 million.

  • Zentalis Pharmaceuticals' EBITDA rose 3441.05% to -$33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.3 million, marking a year-over-year increase of 2102.72%. This contributed to the annual value of -$191.2 million for FY2024, which is 3616.42% up from last year.
  • According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' EBITDA is -$33.7 million, which was up 3441.05% from -$36.1 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year EBITDA high stood at -$24.8 million for Q1 2024, and its period low was -$103.9 million during Q2 2023.
  • In the last 4 years, Zentalis Pharmaceuticals' EBITDA had a median value of -$54.2 million in 2022 and averaged -$55.6 million.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' EBITDA skyrocketed by 6187.24% in 2024, and later plummeted by 8422.37% in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' EBITDA (Quarter) stood at -$51.8 million in 2022, then tumbled by 31.24% to -$67.9 million in 2023, then rose by 26.61% to -$49.8 million in 2024, then skyrocketed by 32.33% to -$33.7 million in 2025.
  • Its last three reported values are -$33.7 million in Q3 2025, -$36.1 million for Q2 2025, and -$45.6 million during Q1 2025.